Personalis, Inc. Hits New 52-Week High of $8.93, Up 546% Year-Over-Year

Personalis, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 8.93 on October 15, 2025. This achievement marks a remarkable increase from its 52-week low of USD 2.83, reflecting a substantial year-over-year performance of 546.21%. The company's market capitalization stands at USD 472 million, positioning it within the microcap category. Despite its impressive stock performance, Personalis, Inc. is currently operating at a loss, as indicated by its negative price-to-earnings ratio. The company also shows a return on equity of -47.85%, and its debt-to-equity ratio is reported at -0.86, suggesting a unique financial structure. With no dividend yield and a price-to-book ratio of 2.47, Personalis, Inc. continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry. The recent price movement underscores the company's evolving market position and the dynamics at play within its sector.